In a groundbreaking study emerging from the Medical University of Vienna, researchers have unveiled a novel mechanism pivotal to understanding and potentially improving therapies against metastatic colorectal cancer. Traditionally, the epidermal growth factor receptor (EGFR), a critical target in cancer therapy, has been studied primarily regarding its influence on the cancerous cells themselves. However, this study shifts focus to the intriguing role EGFR plays within certain immune cells populating the tumour microenvironment, revealing new dimensions to how the body’s immune system interacts with cancer progression.
Colorectal cancer remains a leading cause of cancer mortality globally, with metastatic forms of the disease notably difficult to treat effectively. The advent of targeted therapies against EGFR marked a significant advancement for patients, particularly those lacking certain mutations in the KRAS gene. Despite this precision approach, therapeutic resistance frequently emerges over the treatment course, and a sizable subset of patients demonstrates suboptimal responses. These clinical challenges have driven scientists to explore beyond the carcinoma cells themselves to unravel the complexities influencing treatment outcomes.
The research led by Dr. Maria Sibilia elucidates the multifaceted role of EGFR not only on tumour cells but critically within myeloid cells — an essential class of immune cells including macrophages often implicated in immune regulation and cancer biology. While macrophages typically function as defense agents by clearing pathogens and damaged cellular material, within tumour settings they frequently undergo reprogramming, assuming phenotypes that support tumour growth and foster immune evasion.
Utilizing sophisticated preclinical models complemented by cutting-edge single-cell sequencing and proteomic analyses, the team observed a striking pattern: ablation of EGFR expression specifically in myeloid cells significantly slowed tumour progression. Intriguingly, the deletion of EGFR solely in the colorectal cancer cells did not yield comparable therapeutic benefits. These findings underscore a paradigm shift, suggesting that EGFR-targeted treatments exert part of their clinical efficacy by modulating the immune cells within the tumour microenvironment rather than exclusively targeting the malignant cells themselves.
The microenvironment of a tumour is a complex and dynamic ecosystem, wherein the immune milieu critically dictates tumour fate. The study discovered that silencing EGFR in myeloid cells markedly reduced the secretion of immunosuppressive molecules that normally inhibit T cells. T cells, integral to adaptive immunity, play a decisive role in detecting and destroying cancer cells. When T cell activity is suppressed in the tumour context, cancer can proliferate with fewer immune obstacles, emphasizing the therapeutic promise in fostering T cell activation.
Dr. Sibilia remarks that the presence of EGFR within myeloid cells orchestrates a tumour-promoting immune landscape, tipping the balance away from tumour suppression toward immune evasion and tumour growth. This unexpected insight reveals that antiproliferative effects seen with anti-EGFR therapies might largely stem from reshaping the immune environment, effectively reprogramming it to restore anti-tumour immunity. The data redefine EGFR as a dual-edged player influencing both malignant and immune compartments.
Focusing more narrowly on macrophages, which are notable for their plasticity and association with poor prognoses when polarized towards tumour-promoting states, the study documents a significant decline in these immunosuppressive subpopulations following EGFR removal in myeloid cells. This reduction disrupts the protective niche these cells typically provide to tumours. Concurrently, inflammatory signaling pathways within tumours shifted, altering intercellular communication towards a less suppressive and more immunostimulatory microenvironment.
One particularly compelling molecular revelation centered on thrombospondin-1 (THBS1), a multifunctional glycoprotein secreted by myeloid cells and influential in immune cell crosstalk. The researchers found that EGFR signaling modulates THBS1 expression, positioning this protein as a critical mediator within the immune modulation cascade. Clinically, elevated levels of both EGFR and THBS1 in colorectal cancer patients correlated with poorer outcomes, spotlighting THBS1’s potential as a biomarker for disease progression and the immunological status of the tumour milieu.
This comprehensive investigation opens avenues for innovative therapeutic strategies. Current treatment paradigms predominantly focus on direct tumour targeting, but these findings advocate for a broader approach. Targeted manipulation of EGFR in immune cells, specifically myeloid populations, could recalibrate the tumour microenvironment to favor immune activation and improve patient response rates. Such immunomodulatory strategies could potentially overcome acquired resistance to EGFR blockade by dismantling the tumour’s immunosuppressive shield.
Moreover, the refined understanding of EGFR’s dual roles invites reconsideration of therapeutic design, encouraging combination therapies that encompass both tumour and immune components. This dual-targeting could invigorate endogenous immune defenses while directly stymying tumour cell proliferation. In the era of immunotherapy, integrating insights from this study might transcend current limitations in metastatic colorectal cancer treatment.
Overall, the work spearheaded by the Vienna group highlights the immense complexity and interdependence within tumours, where cancer cells and immune populations engage in a nuanced dialogue mediated by proteins like EGFR and THBS1. Unraveling these pathways offers hope for next-generation therapies that harness the body’s immune power more effectively while mitigating the tumour-supportive roles of certain immune cells. This insight represents a promising frontier toward improved survival outcomes in this challenging malignancy.
Their results, published in the prestigious journal Cell Death & Differentiation, underscore the critical necessity of targeting the tumour microenvironment alongside traditional cancer cells. As metastatic colorectal cancer continues to pose formidable clinical challenges, these findings deliver a fresh perspective, steering future research and clinical trials toward immune-centric approaches that could fundamentally alter treatment landscapes and patient prognoses.
Subject of Research: Role of EGFR in myeloid immune cells and its impact on the tumour microenvironment in metastatic colorectal cancer.
Article Title: EGFR deletion in myeloid cells reprograms the immunosuppressive landscape of colorectal cancer
News Publication Date: 2 June 2026
Web References: https://doi.org/10.1038/s41418-026-01774-x
Keywords: Colorectal cancer, epidermal growth factor receptor, EGFR, myeloid cells, macrophages, tumour microenvironment, immune suppression, thrombospondin-1, THBS1, metastatic cancer, cancer immunotherapy, tumour immunity
Tags: colorectal cancer immune cell researchEGFR role in tumor microenvironmentEGFR targeted therapy resistanceimmune system and colorectal cancerKRAS mutation impact on cancer treatmentmacrophages in tumor immunityMedical University of Vienna cancer studymetastatic colorectal cancer therapiesmyeloid cells in cancer progressionnovel cancer immunotherapy targetsprecision medicine in colorectal cancertumor microenvironment and therapy outcomes
